secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcellx, Inc. (ACLX)
CIK:        0001786205
Form:       8-K
Filed at:   2023-03-29T23:59:59+00:00
Accession:  0000950170-23-010604
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcellx reports 2022 results; announces Kite collaboration for CART-ddBCMA with $325M upfront
--------------------------------------------------------------------------------

- Strategic collaboration with Kite (Gilead): $225M upfront + $100M equity; co-commercialize in US, royalties ex-US.
- Phase 1 expansion data: 100% ORR, 71% CR/sCR in evaluable rrMM patients; no delayed neurotoxicity.
- Pivotal iMMagine-1 trial dosed; Phase 1 ACLX-002 for AML/MDS initiated.
- Cash $254.8M at Dec 31, 2022; plus $325M from Kite/Gilead in Jan 2023; expected to fund through BLA filing H1 2025.
- Net loss $188.7M for FY2022 vs $65.0M in 2021; R&D expenses $149.6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1786205/000095017023010604/0000950170-23-010604-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1786205/000095017023010604/aclx-20230329.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-010604

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer